R&D BIO-Europe Spring 2026: In conversation with Robert Jacks Robert Jacks, CEO of Sparrow Pharmaceuticals, discusses the company’s work in the cardiometabolic space.
News Crystalys emerges with $205m, and other biofinancings Recent biotech financings include big rounds for Crystalys and Star Therapeutics, with Sparrow, Avenzo, and Aerska also raising new funds.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
